News AstraZeneca buys cell therapy biotech for up to $1bn AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.
News Daiichi Sankyo partners Alteogen on subcutaneous Enhertu Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu.
News PTC stung by FDA decision not to approve rare disease drug It looks like PTC will have to carry out another trial of its drug for Friedreich ataxia before the FDA will consider approval.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face